How can we improve patients’ access to new drugs under uncertainties? : South Korea’s experience with risk sharing arrangements

Table 4 Comparison of Korean RSA drugs with the UK, Italy, and Australia

	No. of indications	% of reimbursed
Total	64	100.0
South Korea
RSA
refund	11
expenditure cap	22
refund + expenditure cap	7
others	3
conventional reimbursement	9
sub total	52	81.3
not reimbursed	11
not approved	1
UK
PAS
simple discount	27
complex scheme	5
PAS + CAA	1
conventional reimbursement	5
sub total	38	59.4
CDF	14	21.9
not reimbursed	12
Italy
MEA
financial-based	4
outcome-based	5
conventional reimbursement	50
sub total	59	92.2
not reimbursed	5
Australia
MES	0
financial RSA	2
SPA	4
financial RSA + SPA	26
MES + SPA	1
MES + financial RSA	2
MES + financial RSA + SPA	1
conventional reimbursement	3
sub total	39	60.9
LSDP	3	4.7
not reimbursed	22

RSA risk sharing arrangement, PAS patients access scheme, CAA CDF (cancer drug fund) managed access agreement, CDF cancer drug fund, MEA managed entry agreement, MES managed entry scheme, SPA special pricing arrangements, LSDP life-saving drugs program

ISSN: 1472-6963